We are informing our provider community of two updates to our Commercial member pharmacy benefits, effective April 1, 2024. These updates apply to commercial plans only.
- Insulin Aspart /Insulin Aspart Protamine & Aspart
- Currently, Blue Cross Blue Shield of North Dakota (BCBSND) covers brand Novolog® and Insulin Aspart®/Insulin Aspart Protamine & Insulin Aspart. Effective April 1, 2024, Insulin Aspart /Insulin Aspart Protamine & Aspart (unbranded Novolog /Novolog Mix) will no longer be covered on BCBSND commercial formularies. There will be no changes in coverage of brand Novolog or Novolog Mix. Members may require a new prescription to fill brand Novolog as an alternative.
- Currently, Blue Cross Blue Shield of North Dakota (BCBSND) covers brand Novolog® and Insulin Aspart®/Insulin Aspart Protamine & Insulin Aspart. Effective April 1, 2024, Insulin Aspart /Insulin Aspart Protamine & Aspart (unbranded Novolog /Novolog Mix) will no longer be covered on BCBSND commercial formularies. There will be no changes in coverage of brand Novolog or Novolog Mix. Members may require a new prescription to fill brand Novolog as an alternative.
- Growth Hormone Prior Authorization (GH PA)
- BCBSND is updating the GH PA program summary criteria. Effective April 1, 2024, Norditropin® will be a non-preferred GH agent. Patients will need to trial a preferred GH agent, Genotropin® or Omnitrope™, prior to being eligible for coverage of a non-preferred GH agent. Current Norditropin prior approvals will remain valid for the duration of the approval. Once Norditropin approvals have expired, patients will need to meet the updated GH PA program criteria.
Questions?
Call the benefits contact number on the back of the members insurance card.
